1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

Biden's COVID-19 Advisory Board Bodes Well For Science-Driven FDA

 
• By Sarah Karlin-Smith

Two prominent former US FDA officials are a part of the president-elect’s new COVID-19 advisory board. Biden’s emphasis on scientific independence, including a commitment to publicly release vaccine trial data, could help restore public confidence in the agency and coming COVID-19 vaccines.

11/07/2020, USA: Democratic presidential nominee Joe Biden speaks as vice presidential nominee Sen. Kamala Harris listens at The Queen theater, in Wilmington.
President-elect Biden announced his COVID-19 advisory board 9 November • Source: Shutterstock

The composition of US President-elect Joe Biden’s COVID-19 advisory board announced 9 November is a positive sign that the Food and Drug Administration will be free from the political tinkering that often colored the pandemic response of President Donald Trump's administration, potentially beginning a reversal in recent trends of decreased public trust in the agency and future coronavirus vaccines, experts said.

Two prominent former agency leaders, David Kessler, who served as FDA commissioner under Republican President George HW Bush and Democratic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership

US FDA ‘Commissioner’s Voucher’ As Public Relations Tool

 
• By Michael McCaughan

NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.

HHS Wants Employees (And Public?) To Report Diversity, Equity And Inclusion Discrimination

 
• By Sue Sutter

A survey asks FDA staff to disclose whether DEI policies caused discrimination or resulted in disciplinary action against career employees over the past five years, but uses a web form that the general public also can access.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By Vibha Sharma

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.